Absci To Participate In The 25Th Annual Needham Virtual Healthcare Conference

(MENAFN- GlobeNewsWire - Nasdaq) VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25^th Annual Needham Virtual Healthcare Conference.

Absci management is scheduled to participate in a fireside chat on Thursday, April 16^th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company's investor relations website at: absci.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug CreationTM platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci's approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201TM, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential“best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at or follow us on LinkedIn (@absci ), X (@Abscibio ) and YouTube.

Absci^® standard character mark, ABS-201TM, and Integrated Drug CreationTM are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
...

Media Contact
...

MENAFN08042026004107003653ID1110957097